---
schema_version: "secwatch.filing_event.v1"
accession: "0001703057-26-000033"
form_type: "8-K"
ticker: "ABCL"
cik: "0001703057"
company_name: "AbCellera Biologics Inc."
filed_at: "2026-06-12T16:12:02+00:00"
generated_at: "2026-06-12T16:13:11.244052+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# AbCellera shareholders elect two Class III directors, ratify EY, approve say-on-pay

## Summary
- John S. Montalbano elected with 141.4M for, 12.7M against; Stephen R. Quake with 149.0M for, 5.1M against.
- Ratification of Ernst & Young as independent auditor for FY2026: 190.0M for, 0.6M against.
- Advisory say-on-pay approved: 142.8M for, 10.9M against, with 36.6M broker non-votes.

## SEC filing metadata
- accession: 0001703057-26-000033
- form_type: 8-K
- ticker: ABCL
- cik: 0001703057
- company_name: AbCellera Biologics Inc.
- filed_at: 2026-06-12T16:12:02+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703057/000170305726000033/0001703057-26-000033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703057/000170305726000033/abcl-20260611.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001703057-26-000033
- JSON: https://secwatch.observer/filing/0001703057-26-000033.json
- Plain text: https://secwatch.observer/filing/0001703057-26-000033.txt

## Key facts
- Shareholder Votes
  AbCellera Biologics Inc. shareholders approved Election of John S. Montalbano, CFA, and Stephen R. Quake, D.Phil. as Class III directors at the 2026-06-11 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-11
  source text: The Company’s shareholders approved the election of John S. Montalbano, CFA, and Stephen R. Quake, D.Phil., as Class III directors recommended for election in Proposal 1 at the Annual Meeting. The Company’s shareholders voted for the Class III directors as follows: Nominee For Against Abstain John S. Montalbano, CFA 141,430,732 12,723,342 45,898 Stephen R. Quake, D.Phil. 149,019,960 5,113,056 66,956 The broker non-votes for this Proposal 1 totaled 36,576,359 common shares.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1703057/000170305726000033/0001703057-26-000033-index.htm
- Shareholder Votes
  AbCellera Biologics Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-11 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-11
  source text: The Company’s shareholders approved Proposal 2. The votes cast at the Annual Meeting were as follows: For Against Abstain 189,927,972 552,429 295,930
  evidence_url: https://www.sec.gov/Archives/edgar/data/1703057/000170305726000033/0001703057-26-000033-index.htm
- Shareholder Votes
  AbCellera Biologics Inc. shareholders approved Non-binding advisory vote on compensation of named executive officers (Say-on-Pay) at the 2026-06-11 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-06-11
  source text: The Company’s shareholders approved Proposal 3. The votes cast at the Annual Meeting were as follows: For Against Abstain 142,831,950 10,932,105 435,917 The broker non-votes for this Proposal 3 totaled 36,576,359 common shares.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1703057/000170305726000033/0001703057-26-000033-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.